Declozindol
Experimental wakefulness-promoting research compound, a relative of mazindol; no peer-reviewed studies, not proven in humans.

Pharmacology
Contents
DETAILED OVERVIEW
What is Declozindol?
Declozindol is a little-known experimental research compound described as a wakefulness-promoting agent and considered a chlorine-free relative of mazindol, a known stimulant. It is not approved anywhere and is sold as a substance not intended for human consumption.
Its proposed action is to block the reuptake of noradrenaline (a brain messenger involved in alertness and the stress response) into nerve cells, and it may also moderately affect the orexin system, which regulates wakefulness. There are no peer-reviewed animal or human studies and no reliable source for it, so all information is preliminary and proves neither its safety nor its effectiveness. In theory it could raise heart rate and blood pressure, and cause insomnia and loss of appetite; its long-term safety is unknown. There is no safety data for pregnancy and breastfeeding.
Mechanism
Selective NET reuptake inhibitor
Key target
Norepinephrine transporter (NET)
Evidence level
Reference-only (no human data)
Legal status
Unapproved research compound
Chemical formula
N/A (not reported)
No anecdote collected yet.
Receptor profile
- Norepinephrine transporter (NET)Strong
- Orexin-2 receptor (OX2)Moderate
- Dopamine transporter (DAT)Weak
Safety
Side effects, stop signs, contraindications
Side effects · 4
- Raised heart rate and blood pressure (sympathomimetic effect of NET inhibition)
- Insomnia, disturbed sleep (wakefulness-promoting profile)
- Appetite suppression
- Unknown long-term safety profile (no human data)
Contraindications · 5
- No approved clinical use: strictly an experimental research compound with no human safety data
- Cardiovascular disease (hypertension, arrhythmia): NET inhibition may raise heart rate and blood pressure
- Anxiety disorders, insomnia: the wakefulness-promoting effect may worsen them
- Pregnancy and breastfeeding: no reproductive safety data
- With MAO inhibitors or other noradrenergic agents: additive sympathomimetic risk
Related Nootropics
Same therapeutic category
FAQ
FAQ
Declozindol is an almost entirely unknown experimental research compound, theoretically developed as a wakefulness and anti-fatigue agent, related to a known stimulant. It's important to be honest here: there is essentially no human data on it, every claim is theoretical or based on animal studies, so it should not be treated as an established or reliable substance.
Telegram
Have a question about Declozindol?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.